MRZM Stock Overview
A multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Marizyme, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.045 |
| 52 Week High | US$0.15 |
| 52 Week Low | US$0.018 |
| Beta | 0.14 |
| 11 Month Change | -19.50% |
| 3 Month Change | n/a |
| 1 Year Change | -55.05% |
| 33 Year Change | -96.76% |
| 5 Year Change | -95.00% |
| Change since IPO | -97.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRZM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 145.9% | 2.4% | 2.2% |
| 1Y | -55.0% | 16.2% | 31.7% |
Return vs Industry: MRZM underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: MRZM underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| MRZM volatility | |
|---|---|
| MRZM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRZM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MRZM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | David Barthel | www.marizyme.com |
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It’s product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures.
Marizyme, Inc. Fundamentals Summary
| MRZM fundamental statistics | |
|---|---|
| Market cap | US$5.93m |
| Earnings (TTM) | -US$52.51m |
| Revenue (TTM) | US$364.95k |
16.3x
P/S Ratio-0.1x
P/E RatioIs MRZM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRZM income statement (TTM) | |
|---|---|
| Revenue | US$364.95k |
| Cost of Revenue | US$131.37k |
| Gross Profit | US$233.58k |
| Other Expenses | US$52.75m |
| Earnings | -US$52.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 64.00% |
| Net Profit Margin | -14,389.51% |
| Debt/Equity Ratio | -208.5% |
How did MRZM perform over the long term?
See historical performance and comparison